Technology & Biotech Startup Valuation

At Valtech Valuation, we specialize in technology and biotech startup valuation, leveraging industry-leading methodologies to assess the financial potential of cutting-edge innovations. Our expertise spans biotechnology, life sciences, healthcare, and digital technology startups, helping businesses, investors, and financial institutions make informed investment and strategic decisions.

Biotech Valuation Methodologies

1. Risk-Adjusted Net Present Value (rNPV) Approach

The standard valuation method in the drug development industry, rNPV is an advanced form of the discounted cash flow (DCF) model. At Valtech Valuation, we use a specialized rNPV framework to value biotech enterprises, incorporating:
✔ Market size & share estimates
✔ Projected sales price & revenue forecasts
✔ Cost structure & capital expenditure analysis
✔ Commercialization strategies – Direct market entry vs. partnerships with established pharmaceutical companies

2. Market Approach & Public Transaction Database

To ensure robust valuation results, we cross-check using the Market Approach, benchmarking against public transactions and industry comparables. Our proprietary biotech and healthcare transaction database covers global capital markets, providing deep insights into sector-specific valuations.

3. Clinical Trial Phase-Based Valuation

Given the high uncertainty in biotech startups, we emphasize benchmarking valuations by clinical trial phase. Our approach incorporates comparable listed companies and past transactions, ensuring valuation assumptions are realistic and data-driven.

Therapeutic Areas Covered in Our Valuation Database

✔ Oncology
✔ Immunology
✔ Genetic Testing 
✔ Cardiovascular
✔ Vaccine
✔ Liver Diseases (HCV, HIV, HBV)
✔ Nervous System

Our database provides valuation benchmarks based on clinical stage, commercialization potential, and industry trends, ensuring accurate financial insights for biotech startups and investors.